Business UpdateJul 29, 2026, 07:21 AM
Biodexa Expands FAP Patient Support & eRapa Access in France
AI Summary
Biodexa Pharmaceuticals Plc announced the launch of patient support activities and expanded access for eRapa in France for patients with Familial Adenomatous Polyposis (FAP). The company held its first roundtable in Paris, bringing together patients, advocates, and clinicians to improve outcomes for FAP, a condition with no approved therapeutic options. This initiative complements Biodexa's existing early access program for eRapa, an experimental mTOR inhibitor currently in a Phase 3 clinical trial, which is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas.
Key Highlights
- Biodexa launched patient support activities for Familial Adenomatous Polyposis (FAP) in France.
- The company held its first roundtable in Paris to support FAP patients and prescribers.
- These activities complement the existing early access program for eRapa in FAP.
- eRapa is an experimental mTOR inhibitor, currently in a global early access program.
- eRapa has Orphan Drug Designation in the US and plans to seek it in Europe.
- A Phase 3 clinical trial for eRapa is ongoing, targeting 168 patients across 30 centers.
- The Phase 3 program is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas.
Price Impact
More from BDRX